RxDoctor Payments Data

Dixon Cunningham, MD

Neurology · Anderson, SCNPI 1487647582

Payments from drug & device makers

$7,283in general payments, 2019–2025

Across 323 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$754
  • Novartis$661
  • Teva Pharmaceuticals USA, Inc.$580
  • AbbVie$476
  • Neurocrine Biosciences, Inc.$419
  • EMD Serono, Inc.$412
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$6008%
  • Food & beverage$6,56290%
  • Education$1212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,283 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$210,289
Medicare patients
503
Services billed
18,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate24$152,665
Aimovig AutoinjectorErenumab-Aooe69$59,172
KeppraLevetiracetam15$55,237
AptiomEslicarbazepine Acetate19$31,405
Emgality PenGalcanezumab-Gnlm28$19,527
Carbidopa-LevodopaCarbidopa/Levodopa268$12,566
Carbamazepine ErCarbamazepine44$7,238
Primidone140$7,194
Levetiracetam187$6,475
DilantinPhenytoin Sodium Extended19$6,253
Keppra XrLevetiracetam12$6,192
Gabapentin298$5,775
Divalproex Sodium ErDivalproex Sodium93$4,936
Oxcarbazepine66$4,593
Dimethyl Fumarate18$3,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$580$152,66524 claims
Sunovion Pharmaceuticals Inc.Aptiom$78$31,40519 claims
PfizerDilantin$129$6,25319 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$127$2,83733 claims
Upsher-smith Laboratories LLCTopiramate$18$2,804165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.

Other neurology in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →